Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).
Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
The intervention showed no clear difference in chemotherapy Rates of patients who received the planned chemotherapy… (low certainty).
The intervention probably leads to lower febrile neutropenia Rates of patients (moderate certainty).
The intervention probably leads to higher injection‐site reaction Rates of patients (moderate certainty).
The intervention may leads to lower early mortality Rates of patients (low certainty).
The intervention showed no clear difference in infection‐related mortality Rates of patients (low certainty).
The intervention showed no clear difference in severe neutropenia (WHO grade IV) Rates of patients (moderate certainty).
The intervention showed no clear difference in infections Rates of patients (low certainty).
The intervention may leads to lower hospitalization Rates of patients (low certainty).
The intervention may leads to lower antibiotics (i.v.) Rates of patients (low certainty).
The intervention probably leads to higher bone pain Rates of patients (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).